MAPT and Alzheimer disease: The ability for plasma levels of Aβ42 and tau to aid in clinical diagnosis of AD were evaluated vigorously as performance metrics in this study, based on areas under the curve (AUC) of ROC, which were compared using LOO cross-validation to avoid over-fitting.